Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kazia Therapeutics Limited KZIA
$1.33
+$0.02 (1.87%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
26948095.00000000
-
week52high
6.97
-
week52low
0.50
-
Revenue
25
-
P/E TTM
-1
-
Beta
2.24580100
-
EPS
-1.15000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 янв 2023 г. в 05:00
Описание компании
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 02 авг 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 02 авг 2022 г. |
| Maxim Group | Buy | 14 окт 2021 г. | |
| HC Wainwright & Co. | Buy | 05 янв 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| AUSTIN JOSIAH T | D | 385749 | 23922 | 05 ноя 2013 г. |
| AUSTIN JOSIAH T | D | 409671 | 25400 | 04 ноя 2013 г. |
| AUSTIN JOSIAH T | D | 435071 | 1100 | 29 окт 2013 г. |
| AUSTIN JOSIAH T | D | 436171 | 37409 | 28 окт 2013 г. |
| AUSTIN JOSIAH T | D | 473580 | 62591 | 25 окт 2013 г. |
| AUSTIN JOSIAH T | D | 536171 | 90025 | 15 окт 2013 г. |
| AUSTIN JOSIAH T | D | 626196 | 500 | 26 февр 2013 г. |
| AUSTIN JOSIAH T | D | 628196 | 500 | 25 февр 2013 г. |
| AUSTIN JOSIAH T | D | 629196 | 500 | 25 февр 2013 г. |
| AUSTIN JOSIAH T | D | 626696 | 500 | 25 февр 2013 г. |
Новостная лента
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
PRNewsWire
09 сент 2022 г. в 08:00
SYDNEY , Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Global Investment Conference, held in New York, NY, from 12 – 14 September 2022.
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
PRNewsWire
08 сент 2022 г. в 08:30
SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France.
Kazia Therapeutics (KZIA) Stock Soars on FDA Designation
InvestorPlace
06 июл 2022 г. в 10:56
Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. The post Kazia Therapeutics (KZIA) Stock Soars on FDA Designation appeared first on InvestorPlace.
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
PRNewsWire
23 мая 2022 г. в 08:30
SYDNEY , May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC Wainwright Global Investment Conference, to be held in person and virtually in Miami, FL, from 23-26 May 2022.
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
PRNewsWire
29 апр 2022 г. в 11:00
SYDNEY , April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO). The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022 and will be held in Chicago, IL.